公开(公告)号：US20240392008A1

公开(公告)日：2024-11-28

申请号：US18568310

申请日：2022-06-08

Applicant: INNATE PHARMA

Inventor： Laurent GAUTHIER ,  Yannis MOREL ,  Olivier DEMARIA

IPC: C07K16/28 ,  A61K38/00 ,  C07K14/55

Abstract: Multispecific proteins that bind NKp46 and specifically redirect effector cells to lyse a target cell of interest via multiple receptors are provided. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20240199750A1

公开(公告)日：2024-06-20

申请号：US18283385

申请日：2022-03-24

Applicant: INNATE PHARMA

Inventor： Stephanie CORNEN ,  Laurent GAUTHIER ,  Yannis MOREL ,  Olivier DEMARIA

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K14/54 ,  C07K14/55 ,  C07K14/56 ,  C07K14/565 ,  C12N5/0783

CPC classification number: C07K16/2866 ,  A61P35/00 ,  C07K14/54 ,  C07K14/5418 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/56 ,  C07K14/565 ,  C07K16/2803 ,  C07K16/283 ,  C12N5/0646 ,  A61K39/00 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/92 ,  C07K2319/30

Abstract: Multi-specific proteins that bind to NKp46 and a cytokine receptor on NK cells, and optionally that further bind CD16A on NK cells, and that also bind to an antigen of interest (e.g. a cancer antigen) on a target cell (e.g. a cancer cell). The multi-specific proteins are capable of increasing NK cell cytotoxicity toward a target cell that expresses the antigen of interest (e.g., a cell that contributes to disease, a cancer cell).